On-Q-ity Sees CTC Test Value for Pharma Studies, PGx Efforts

In an interview with GenomeWeb Daily News, On-Q-ity CEO Mara Aspinall touted the advantages of the firm's platform and discussed its potential to monitor patients in clinical trials at a level not currently possible.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories